HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marketing in Brief: SmithKline Beecham

This article was originally published in The Rose Sheet

Executive Summary

SmithKline Beecham: Signs agreement with Foster City, Calif.-based Penederm to develop an OTC product using Penederm's TopiCare delivery compounds, Penederm said April 8. The product will be launched in about a year. TopiCare "traps" an active ingredient in the upper layers of skin, Penederm explained, to prevent wash-off and modulate the absorption of the active into the skin. Under the deal, SmithKline holds the exclusive option to market the finished product worldwide, and Penederm will receive milestone payments and royalties on product sales in addition to the licensing fee for use of the technology. SmithKline's topical offerings include the Oxy line of acne products in the U.S. and Rx Vectavir penciclovir 1% cream for cold sores, currently sold in the U.K. This is the second collaboration for the two companies; the firms signed an agreement in 1996 for a product that is not yet on shelves, SmithKline said...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS004029

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel